[
    {
        "file_name": "revolutionmedicinesinc_20200117_s-1_ex-10.1_11948417_ex-10.1_development agreement.pdf",
        "perturbation": [
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "1.38 “FTE” means a full time equivalent person year (consisting of [***] hours per year) of work as an employee or contractor [***] hereunder as tracked by each Party using its respective standard practice and methodologies. For clarity, [***] will not constitute FTEs. Notwithstanding the foregoing, the time of a single individual will not account for more than one FTE for a given Calendar Year (or applicable pro-rata portion of an FTE during any Calendar Quarter or other period of less than a Calendar Year).",
                "changed_text": "1.38 “FTE” means a full time equivalent person year (consisting of [***] hours per year) of work as an employee [***] hereunder as tracked by each Party using its respective standard practice and methodologies. For clarity, [***] will not constitute FTEs. Notwithstanding the foregoing, the time of a single individual may account for more than one FTE for a given Calendar Year (or applicable pro-rata portion of an FTE during any Calendar Quarter or other period of less than a Calendar Year) subject to internal policy.",
                "explanation": "The original text defines FTE as either employee or contractor. The modified version limits this to 'employee' only, and it changes the individual FTE count to be more than one FTE. This affects cost calculations and resource allocation.",
                "location": "1.38"
            },
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "5.7 Diligence. Consistent with [***] or as otherwise agreed by the Parties, Sanofi shall use Commercially Reasonable Efforts [***] to file and seek approval for an MAA for at least one Product in all of such countries or, in the case of the Major Market Countries in the European Union, through the centralized European Union approval process. If Sanofi materially breaches its obligation set forth in this Section 5.7, [***].",
                "changed_text": "5.7 Diligence. Consistent with [***] or as otherwise agreed by the Parties, Sanofi may use its Business Judgement [***] to file and seek approval for an MAA for at least one Product in all of such countries or, in the case of the Major Market Countries in the European Union, through the centralized European Union approval process. If Sanofi determines, in its sole discretion, not to file for approval, then [***].",
                "explanation": "The original text imposes a 'Commercially Reasonable Efforts' obligation. The modified version replaces this with 'Business Judgement', removing the diligence standard and giving Sanofi complete discretion. It’s contradictory, creating a loophole where Sanofi can avoid obligations.",
                "location": "5.7"
            },
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "9.5 Payment Terms; Exchange Rate. Notwithstanding any term to the contrary of this Agreement, RevMed shall deliver an invoice to Sanofi for all payments owed by Sanofi to RevMed under this Agreement. Sanofi will make all payments owed to RevMed within [***] after the date on which Sanofi receives an undisputed invoice for such owed amount, except where a different timeframe is expressly provided in another Section of this Agreement (e.g., for the reimbursement of RevMed R&D Costs pursuant to Sections 4.5 and 5.5; the payment of the buy-in payment pursuant to Section 5.6(b)B; the upfront payment set forth in Section 9.1; the royalties payable pursuant to Section 9.3, the payment of VAT pursuant to Section 9.7(b); and the payment of unpaid or overpaid amounts pursuant to Section 9.9(b)). All payments to be made by a Party to the other Party under this Agreement shall be made in Dollars by bank wire transfer in immediately available funds to a bank account designated by written notice from the Party that receives the payment.",
                "changed_text": "9.5 Payment Terms; Exchange Rate. Notwithstanding any term to the contrary of this Agreement, RevMed shall deliver an invoice to Sanofi for all payments owed by Sanofi to RevMed under this Agreement. Sanofi will endeavor to make all payments owed to RevMed when Sanofi receives an invoice for such owed amount. All payments to be made by a Party to the other Party under this Agreement may be made in a mutually agreed form. ",
                "explanation": "Original enforces Sanofi to make payments in a specific timeframe and currency, whereas the changed text introduces an obligation of only trying and to make payments when possible, and remove the term immediately available, which will contradict to the rest of the payment terms of the legal document.",
                "location": "9.5"
            }
        ]
    }
]